Focal neurological signs and symptoms induced by interferon-alpha in two patients with malignant melanoma
Rudolf Herbst(Helios Klinikum Erfurt), Johannes M. Weiss(University Hospital Ulm), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Alexander Kapp(Medizinische Hochschule Hannover), E. G. Jung(Heidelberg University)
Cited by 5
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k